This study is to evaluate the safety and tolerability of single or multiple doses of the investigational drug KAN-101 subjects with confirmed celiac disease. This drug targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact.  KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens. 

Eligible participants must be male or female patients ?18 and ?70 at the time of initial screening.

Subjects may be assigned to one of two parts in the study:

Part A involves taking one dose of KAN-101.

Part B involves taking three doses of KAN-101 or placebo, completing a daily questionnaire about celiac symptoms, and undergoing a 3-day high-dose gluten challenge to help assess immune cell activation.